A Critical Evaluation of the Role of Lp(a) in Cardiovascular Disease: Can Lp(a) Be Useful in Risk Assessment?

Santica M. Marcovina; Marlys L. Koschinsky

doi:10.1055/s-2002-35404

Seminars in Vascular Medicine, Inhaltsverzeichnis

Semin Vasc Med 2002; 02(3): 335-344
DOI: 10.1055/s-2002-35404

A Critical Evaluation of the Role of Lp(a) in Cardiovascular Disease: Can Lp(a) Be Useful in Risk Assessment?

Santica M. Marcovina¹ , Marlys L. Koschinsky²

¹Department of Medicine, Northwest Lipid Research Laboratories, University of Washington, Seattle, WA
²Department of Biochemistry, Queen's University, Kingston, Ontario, Canada.

Abstract

ABSTRACT

Lp(a) is a structurally complex particle which resembles LDL, but which also contains the distinctive glycoprotein apo(a). Apo(a) is characterized by a variable number of repeated kringle domains, which gives rise to differently-sized Lp(a) isoforms in the population. Although epidemiological studies indicate that elevated Lp(a) concentration and/or small apo(a) isoform sizes increase the risk of coronary heart disease (CHD), a causal role for Lp(a) in CHD remains unproven. This is largely due to the difficulty in establishing a relevant animal model to probe Lp(a) function, and the lack of intervention studies in which Lp(a) concentrations are lowered and outcomes followed. The accumulation of apo(a)/Lp(a) in arterial lesions has provided the rationale for numerous in vitro studies aimed at dissecting its function in this milieu. These studies have resulted in the proposal of numerous proatherogenic, prothrombotic and antifibrinolytic roles for both native and modified apo(a)/Lp(a). Although characterization of Lp(a) in the general population is not presently justified, Lp(a) analysis in patients at risk for CHD may be warranted.

KEYWORDS

Lipoprotein(a) - apolipoprotein(a) - coronary heart disease - atherosclerosis

Volltext

Referenzen

REFERENCES

1 Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand . 1963; 59 362-382
2 Cheng S W, Ting A C, Wong J. Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur Vasc Endovasc Surg . 1997; 14 17-23
3 Peng D Q, Zhao S P, Wang J L. Lipoprotein(a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk . 1999; 6 1-6
4 Marcovina S M, Hegele R A, Koschinsky M L. Lipoprotein(a) and coronary heart disease risk. Curr Cardiol Rep . 1999; 1 105-111
5 Marcovina S M, Koschinsky M L. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol . 1998; 82 57U-66U
6 Craig W Y, Neveux L M, Palomaki G E. Lipoprotein(a) as a risk factor for ischemic heart disease: meta-analysis of prospective studies. Clin Chem . 1998; 44 2301-2306
7 Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: meta-analysis of prospective studies. Circulation . 2000; 102 1082-1085
8 Armstrong V W, Cremer P, Eberle E. The association between serum Lp(a) concentrations and angiographically-assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis . 1986; 62 249-257
9 Maher V M, Brown B G, Marcovina S M. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA . 1995; 274 1771-1774
10 Hopkins P N, Wu L L, Hunt S C. Lipoprotein(a) interactions with lipid and nonlipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol . 1997; 17 2783-2792
11 Cantin B, Gagnon F, Moorjani S. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men?. <~>The Quebec Cardiovascular Study. J Am Coll Cardiol . 1998; 31 519-525
12 Kronenberg F, Kronenberg M F, Kiechl S. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. Circulation . 1999; 100 1154-1160
13 van Eckardstein A, Schulte H, Cullen P. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol . 2001; 37 434-439
14 Marcovina S M, Koschinsky M L. Lipoprotein(a): Structure, measurement, and clinical significance. In: Rifai, N, Warnick, GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing, Ed 2. Washington, DC AACC Press 345-385
15 Angelin B. Therapy for lowering lipoprotein(a) levels. Curr Opin Lipidol . 1997; 8 337-341
16 Albers J J, Kennedy H, Marcovina S M. Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: evaluation of amino acid analysis data. J Lipid Res . 1996; 37 192-196
17 Koschinsky M L, Côté G P, Gabel B R. Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem . 1993; 268 19819-19825
18 Callow M J, Rubin E M. Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo J Biol Chem . 1995; 270 23914-23917
19 Trieu V N, McConathy W J. A two-step model for lipoprotein(a) formation. J Biol Chem . 1995; 270 15471-15474
20 Gabel B R, Koschinsky M L. Sequences within apolipoprotein(a) kringle IV types 6-8 bind directly to low-density lipoprotein and mediate noncovalent association of apolipoprotein(a) with apolipoprotein B-100. Biochemistry . 1998; 37 7892-7898
21 Becker L, McLeod, R, Marcovina S M. Identification of a critical lysine residue in apolipoprotein B-100 that mediates noncovalent interaction with apolipoprotein(a) (in press). J Biol Chem.
22 Xu S. Apolipoprotein(a) binds to low density lipoprotein at two distant sites in lipoprotein(a). Biochemistry . 1998; 37 9284-9294
23 White A L, Rainwater D L, Lanford R E. Intracellular maturation of apolipoprotein(a) and assembly of lipoprotein(a) in primary baboon hepatocytes. J Lipid Res . 1993; 34 509-517
24 Frank S, Krasznai K, Durovic S. High-level expression of various apolipoprotein(a) isoforms by ``transferrinfection'': the role of kringle IV sequences in the extracellular association with low-density lipoprotein. Biochemistry . 1994; 33 12329-12339
25 White A L, Lanford R E. Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. J Biol Chem . 1994; 269 28716-28723
26 Fless G M, ZumMallen M E, Scanu A M. Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem . 1986; 261 8712-8718
27 Kraft H G, Menzel H J, Hopplichler F. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest . 1989; 83 137-140
28 McLean J W, Tomlinson J E, Kuang W-J. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature . 1987; 330 132-137
29 Lackner C, Cohen J C, Hobbs H H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet . 1993; 2 933-940
30 van der Hoek Y Y, Wittekoek M E, Beisiegel U. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms. Hum Mol Genet . 1993; 2 361-366
31 Sangrar W, Marcovina S M, Koschinsky M L. Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cells. Protein Eng . 1993; 7 723-731
32 Gabel B R, May L F, Marcovina S M. Lipoprotein(a) Assembly. Quantitative assessment of the role of apo(a) kringle IV types 2-10 in particle formation. Arterioscler Thromb Vasc Biol . 1996; 16 1559-1567
33 Ernst A, Helmhold M, Brunner C. Identification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a). J Biol Chem . 1994; 270 6227-6234
34 Utermann G, Menzel H J, Kraft H G. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest . 1987; 80 458-465
35 Brunner C, Lobentanz E M, Petho-Schramm A. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem . 1996; 13 32403-32410
36 Gaw A, Brown E A, Ford I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vasc Biol . 1998; 18 1870-1876
37 Rath M, Niendorf A, Reblin T. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis . 1989; 9 579-592
38 Fan J, Shimoyamada H, Sun H. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesions in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol . 2001; 21 88-94
39 Dangas G, Mehran R, Harpel P C. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol . 1998; 32 2035-2042
40 Hoff H F, O'Neil J, Yashiro A. Partial characterization of lipoproteins containing apo(a) in human atherosclerotic lesions. J Lipid Res . 1993; 34 789-798
41 Scanu A M. Proteolytic modifications of lipoprotein(a): potential relevance to its postulated atherothrombogenic role. J Investig Med . 1998; 46 359-363
42 Edelstein C, Italia J A, Scanu A M. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. J Biol Chem . 1997; 272 11079-11087
43 Edelstein C, Shapiro S D, Klezovitch O. Matrix metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. J Biol Chem . 1999; 274 10019-10023
44 Scanu A M, Edelstein C, Klezovitch O. Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix. Trends Cardiovasc Med . 1999; 9 196-200
45 Mooser V, Marcovina S M, White A L. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest . 1996; 98 2414-2424
46 Mooser V, Seabra M C, Abedin M. Apolipoprotein(a) kringle 4-containing fragments in human urine. J Clin Invest . 1996; 97 858-864
47 Kostner K M, Maurer G, Huber K. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol . 1996; 16 905-911
48 Haberland M E, Fless G M, Scanu A M. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem . 1992; 267 4143-4151
49 Naruszewicz M, Selinger E, Davignon J. Oxidative modification of lipoprotein(a) and the effect of beta-carotene. Metabolism . 1992; 41 1215-1224
50 Sattler W, Kostner G M, Waeg G. Oxidation of lipoprotein Lp(a). A comparison with low density lipoproteins. Biochim Biophys Acta . 1991; 1081 65-74
51 Jurgens G, Chen Q, Esterbauer H. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B and apolipoprotein(a). Arterioscler Thromb . 1993; 13 1689-1699
52 Scanu A M. Atherothrombogenicity of lipoprotein(a): the debate. Am J Cardiol . 1998; 82 26Q-33Q
53 Hoover-Plow J, Khaitan A, Fless G M. Phospholipase A2 modification enhances lipoprotein(a) binding to the subendothelial matrix. Thromb Haemost . 1998; 79 640-648
54 Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin Thromb Hemost . 1996; 22 525-542
55 Sangrar W, Bajzar L, Nesheim M E. The antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry . 1995; 34 5151-5157
56 Palabrica T M, Liu A C, Aronovitz M J. Antifibrinolytic effect of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med . 1995; 1 256-259
57 Biemond B J, Friederich P W, Koschinsky M L. Apolipoprotein(a) attenuates fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation . 1997; 96 1612-1615
58 Rand M L, Sangrar W, Hancock M A. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide, SFLLRN. Arterioscler Thromb Vasc Biol . 1998; 18 1393-1399
59 Etingen O R, Hajjar D P, Hajjar K A. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem . 1991; 266 2459-2465
60 Li X N, Grenett H E, Benza R L. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol . 1997; 17 3215-3223
61 Buechler C, Ullrich H, Ritter M. Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood . 2001; 97 981-986
62 Kojima S, Harpel P C, Rifkin D B. Lipoprotein(a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol . 1991; 113 1439-1445
63 Grainger D J, Kirschenlohr H L, Metcalfe J C. The proliferation of human smooth muscle cells is promoted by lipoprotein(a). Science . 1993; 260 1655-1658
64 Grainger D J, Kemp P R, Liu A C. Activation of transforming growth factor beta is inhibited in transgenic apolipoprotein(a) mice. Nature . 1994; 370 460-462
65 Desmaris R L, Sarembock I J, Ayers C R. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation . 1995; 91 1403-1409
66 Miyata M, Biro S, Arima S. High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. Am Heart J . 1996; 130 269-273
67 Adams M R, Kinlay S, Blake C J. Atherogenic lipids and endothelial dysfunction: mechanisms in the genesis of ischemic disorders. Annu Rev Med . 2000; 51 149-167
68 Haque N, Zhang X, French D L. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation . 2000; 102 786-792
69 Allen S, Khan S, Tam S-P. Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. FASEB J . 1998; 12 1765-1776
70 Zhao S P, Xu D Y. Oxidized lipoprotein(a) enhanced the expression of P-selectin in cultured human umbilical vein endothelial cells. Thromb Res . 2000; 100 501-510
71 Takami S, Yamashita S, Kihara S. Lipoprotein(a) enhances the expression of intercellular adhesion molecule-1 in cultured human umbilical vein endothelial cells. Circulation . 1998; 97 721-728
72 Zhao S P, Xu D Y. Oxidized lipoprotein(a) increases the expression of platelet-derived growth factor-B in human umbilical vein endothelial cells. Clin Chim Acta . 2000; 296 121-133
73 Galle J, Schneider R, Heinloth A. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int . 1999; 55 1450-1461
74 Schachinger V, Halle M, Minners J. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol . 1997; 30 927-934
75 Moeslinger T, Friedl T, Volf I. Inhibition of inducible nitric oxide synthesis by oxidized lipoprotein(a) in a murine macrophage cell line. FEBS Lett . 2000; 478 95-99
76 Zampoulakis J D, Kyriakousi A A, Poralis K A. Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes. Clin Cardiol . 2000; 23 895-900
77 Ganne F, Vasse M, Beaudeux J L. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins-consequences for plasmin generation and monocyte adhesion. Thromb Haemost . 1999; 81 594-600
78 Fortunato J E, Bassiouny H S, Song R H. Apolipoprotein(a) fragments in relation to human carotid plaque instability. J Vasc Surg . 2000; 32 555-563
79 Kraft H G, Lingenhel A, Kochl S. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary artery disease. Arterioscler Thromb Vasc Biol . 1996; 16 713-719
80 Linden T, Taddei-Peters W, Wilhelmsen L. Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis . 1998; 137 175-186
81 Marcovina S M, Albers J J, Wijsman E. Differences in Lp(a) concentrations and apo(a) polymorphs between Black and White Americans. J Lipid Res . 1996; 37 2569-2585
82 Paultre F, Pearson T A, Weil H F. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol . 2000; 20 2619-2624
83 Wild S H, Fortmann S P, Marcovina S M. A prospective case-control study of lipoprotein levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol . 1997; 17 239-245
84 Hervio L, Girard-Globa A, Durlach A. The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentrations of each of the apolipoprotein(a) isoforms and their affinity for fibrin. Eur J Clin Invest . 1996; 26 411-417
85 Koschinsky M L, Marcovina S M. The effect of hormone replacement therapy on lipoprotein(a) levels in post-menopausal women. Cardiovascular Rev Rep . 1999; 7 387-394